Carlton Fenzl, MD
Ophthalmology · Bettendorf, IANPI 1386958064
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,404 of the $8,180 with a category attached, or 66.1%. 22 manufacturers reported payments, led by Rxsight Inc at 46.9% of the total. Reporting peaked in 2024 at $4,397 and has fallen 77.1% since, to $1,008 in 2025.
Across 116 payments — averaging $70.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$4K
- Alcon$2K
- Glaukos Corporation$551
- Bausch & Lomb Americas Inc.$476
- Johnson & Johnson Surgical Vision, Inc.$203
- Mallinckrodt Hospital Products Inc.$154
- plus $1K from 16 others
What the payments were for
- Consulting fees$2,75034%
- Speaking & faculty fees$260%
- Food & beverage$5,40466%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 18 | $3,837 |
| Alcon | 44 | $1,543 |
| Glaukos Corporation | 11 | $551 |
| Bausch & Lomb Americas Inc. | 9 | $476 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $203 |
| Mallinckrodt Hospital Products Inc. | 3 | $154 |
| Ocular Therapeutix, Inc. | 5 | $144 |
| Sun Pharmaceutical Industries Inc. | 2 | $143 |
| Harrow Eye, LLC | 3 | $143 |
| Rayner Intraocular Lenses Limited | 4 | $140 |
| Genentech USA, Inc. | 1 | $125 |
| Novartis | 2 | $125 |
| Biogen | 2 | $117 |
| Regeneron Healthcare Solutions, Inc. | 1 | $100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $99 |
| Genentech, Inc. | 1 | $94 |
| Aerie Pharmaceuticals, Inc. | 1 | $84 |
| AbbVie | 2 | $33 |
| Omeros Corporation | 1 | $19 |
| The Cameron-ehlen Group, Inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Lensar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$3,171
- RXSIGHT INJECTOR CARTRIDGE$3,171
- RXSIGHT INJECTOR HANDPIECE$3,171
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$3,171
- LIGHT ADJUSTABLE LENS (LAL)$3,065
- Clareon$287
- XIPERE$151
- VYZULTA$151
- Tecnis IOL$131
- ACTHAR$127
- iStent$126
- iStent inject W$126
- IACCESS$126
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$125
- VABYSMO$125
- MIEBO$125
- CEQUA$116
- Centurion$110
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$106
- VEVYE$104
How this compares
$8,180 in reported general payments places this provider in the 85th percentile of 172 ophthalmology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 83 | $75,544 |
| Prednisolone Acetate | 1,012 | $49,552 |
| ProlensaBromfenac Sodium | 112 | $39,146 |
| LumiganBimatoprost | 48 | $16,747 |
| MoxifloxacinMoxifloxacin Hcl | 744 | $15,501 |
| Bromfenac Sodium | 66 | $12,173 |
| Cyclosporine | 28 | $11,541 |
| Ketorolac Tromethamine | 411 | $7,621 |
| CombiganBrimonidine Tartrate/Timolol | 22 | $6,794 |
| Fluorometholone | 76 | $5,631 |
| Loteprednol Etabonate | 29 | $4,962 |
| Lotemax SmLoteprednol Etabonate | 18 | $4,486 |
| Brimonidine Tartrate | 38 | $3,754 |
| ValacyclovirValacyclovir Hcl | 69 | $2,828 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 29 | $2,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $33 | $99,085153 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm | $99 | $48,594159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 172 ophthalmology providers in Iowa.
Other ophthalmology in Bettendorf
- Martin O'MalleyBettendorf$4K
- Lisa ArbisserBettendorf$3K
- Richard YemmBettendorf$3K
- Edward HuHiawatha$160K
- Michael AbramoffIowa City$158K
- Stephen RussellIowa City$137K
- Jared NielsenWest Des Moines$117K
- Matthew RauenWest Des Moines$108K
- Jason JonesSioux City$83K
- Christy BensonDes Moines$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.